Shire willing to back $64 billion Takeda bid, market signals doubts

LONDON/NEW YORK/TOKYO (Reuters) - Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company this year.

Shire willing to back $64 billion Takeda bid, market signals doubts
Read More


Bagikan Berita Ini